Time course-treated CLL cells showed an increase in LC3A/B-II level at 24, 48, and 72 hr of AZD1208 exposure further indicating that increases in autophagy were sustained during the three days of treatment. The gene discussed is MAP1LC3A; the disease is B-cell chronic lymphocytic leukemia.